Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?

Item

http://www.wikidata.org/entity/Q36723903

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Risk of chemotherapy-induced f ...... ming of administration matter?

@ast

Risk of chemotherapy-induced f ...... ming of administration matter?

@en

type

Item

label

Risk of chemotherapy-induced f ...... ming of administration matter?

@ast

Risk of chemotherapy-induced f ...... ming of administration matter?

@en

prefLabel

Risk of chemotherapy-induced f ...... ming of administration matter?

@ast

Risk of chemotherapy-induced f ...... ming of administration matter?

@en

P1476

Risk of chemotherapy-induced f ...... ming of administration matter?

@en

P2093

Derek Weycker

http://www.w3.org/2001/XMLSchema#string

Jacqueline Figueredo

http://www.w3.org/2001/XMLSchema#string

May Hagiwara

http://www.w3.org/2001/XMLSchema#string

Rich Barron

http://www.w3.org/2001/XMLSchema#string

Spiros Tzivelekis

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Li

http://www.w3.org/2001/XMLSchema#string

P2860

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.

A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.

Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.

Risk of mortality in patients with cancer who experience febrile neutropenia.

P2888

s00520-015-3036-7

P304

2309-2316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-015-3036-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284729486

http://www.w3.org/2001/XMLSchema#string

P698

26607482

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy-induced febrile neutropenia

chemotherapy

P932

4805705

http://www.w3.org/2001/XMLSchema#string